Skip to main content
. Author manuscript; available in PMC: 2020 Feb 6.
Published in final edited form as: Expert Rev Clin Immunol. 2019 Apr 22;15(6):639–656. doi: 10.1080/1744666X.2019.1596800

Figure 2.

Figure 2.

Estimated occurrence and overlapping nature of mast cell mediator disorders with respect to clonal and non-clonal subtypes: (a) clinical signs and symptoms; (b) documentation of increased serum and/or 24 h urine mast cell mediators or their metabolites; and (c) reduction in symptoms following treatment with drugs that inhibit stimulation of mast cells or the action of their mediators.